Orlistat Reduces Uric Acid in Overweight/Obese Patients With Hyperuricemia

Uric Acid Clinical Trial

Official title:
Observational Study on Clinical Efficacy and Safety of Orlistat in Reducing Uric Acid in Overweight/Obese Patients With Hyperuricemia

Status Completed

Clinical Trial Summary

To clarify the uric acid-lowering efficacy of orlistat in overweight/obese patients with hyperuricemia, and to evaluate the safety of orlistat treatment

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05496075
Study type	Interventional
Source	Shanghai 10th People's Hospital
Contact
Status	Completed
Phase	Phase 4
Start date	August 26, 2022
Completion date	December 1, 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05943821` - The Effect of Allopurinol on the Risk of Cardiovascular Events in Patients With Cardiovascular Risk	Phase 3
Recruiting	`NCT05402735` - Value of Uric Acid as Early Predictor of Lupus Nephritis
Recruiting	`NCT04953533` - Research and Development of a New Technology for Detection of Abnormal Excretion of Intestinal Uric Acid Involved in the Incidence of Gout
Recruiting	`NCT04960527` - Acute Effects of Tart Cherry on Uric Acid and Biomarkers of CVD Risk in Healthy Individuals	N/A
Completed	`NCT03531203` - The Effect of Soursop Supplementation on Blood Pressure, Serum Uric Acid and Kidney Function in Prehypertensive Patients	N/A